Skip to Content

Viekira Pak Approval History

FDA Approved: Yes (First approved December 19, 2014)
Brand name: Viekira Pak
Generic name: ombitasvir/paritaprevir/ritonavir with dasabuvir
Dosage form: Tablets
Company: AbbVie Inc.
Treatment for: Hepatitis C

Viekira Pak (ombitasvir/paritaprevir/ritonavir with dasabuvir) is an NS5A inhibitor, NS3/4A protease inhibitor and CYP3A inhibitor combination co-packaged with a non-nucleoside NS5B palm polymerase inhibitor for the treatment of patients with genotype 1 chronic hepatitis C virus (HCV) infection.

Development History and FDA Approval Process for Viekira Pak

DateArticle
Dec 19, 2014Approval FDA Approves Viekira Pak (ombitasvir/paritaprevir/ritonavir with dasabuvir) to Treat Hepatitis C
Apr 22, 2014AbbVie Submits NDA to FDA for Oral, Interferon-Free Therapy for the Treatment of Hepatitis C

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide